Zenith Drugs Ltd (ZENITHDRUG) is currently trading at 39.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Zenith Drugs Limited is a pharmaceutical manufacturer and trader operating a WHO GMP‑certified facility in Indore that produces ORS powder, liquid orals, ointments, liquid externals, capsules and, increasingly, tablets after recent capacity investments, selling through domestic channels and a network of international partners while expanding direct exports. In FY2025-26 Zenith Drugs reported revenue of ₹171.22 crore, a 28.52% year-on-year increase, with EBITDA rising 7.0% to ₹17.26 crore while PAT declined to ₹3.94 crore primarily due to higher depreciation following commissioning of the new tablet line; management expects operating leverage to improve as utilisation increases. Working capital dynamics improved materially, with collection period shortening from around 175 days to 143 days and inventory days reducing from 135 to 122, while net worth increased to ₹73.32 crore and debt‑equity ratio improved from 0.93 to 0.75, indicating strengthening liquidity and reduced leverage. The company is strategically entering chronic therapy segments—cardio‑diabetes and neuropsychiatry—with several tablet formulations lined up including Empagliflozin, Empagliflozin with Metformin, Sitagliptin variants, Vildagliptin variants and Ticagrelor, reflecting a deliberate move toward higher‑value, differentiated product categories. Zenith continues to expand its international footprint with approvals in Afghanistan, Cambodia, Liberia and Myanmar, works with over 25 global partners, and is establishing direct export distribution in Liberia for BVM’s ORS, demonstrating a dual focus on export growth and greater control over selected overseas market channels.

Over the past 52 weeks, Zenith Drugs Ltd has traded between a low of ₹33.30 and a high of ₹65.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Zenith Drugs Ltd has a market capitalization of approximately 67.65. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Zenith Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.13 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 67.65 Cr, Zenith Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Zenith Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Zenith Drugs Ltd is 17.13. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.